Langenbeck's Archives of Surgery

, Volume 390, Issue 6, pp 503–509 | Cite as

Standards of medical treatment and nutrition in Crohn’s disease

Current Concepts in Clinical Surgery


Crohn’s disease is a condition of chronic inflammation potentially involving any location of the alimentary tract from mouth to anus but with a propensity for the distal small bowel and proximal large bowel. Frequent complications include stricture and fistula. Numerous extra-intestinal manifestations may also be present. The aetiology of Crohn’s disease is incompletely understood, and therapy, although generally effective in alleviating the symptoms, is not curative. Due to the heterogeneity of the disease a major need for the therapeutic approach is the ability to define subgroups with distinct characteristics. However, with regard to the heterogeneity of demographic, anatomic and disease behaviour characteristics, distilling the numerous possible phenotypes in simple categories is a formidable task. In the present review the focus will be on clinically relevant situations providing therapeutic algorithms according to international guidelines.


Crohn’s disease Therapy Immunosuppressive agents 5-Aminosalicylates Corticosteroids Nutrition 


  1. 1.
    Fiocchi C (1998) Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115:182–205PubMedGoogle Scholar
  2. 2.
    Gasche C, Schölmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, et al (2000) A simple classification of Crohn’s disease: report of Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 6:8–15PubMedGoogle Scholar
  3. 3.
    Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, et al (1990) Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98:811–818PubMedGoogle Scholar
  4. 4.
    Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al (1994) Oral budesonide for active Crohn’s disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med 331:836–841CrossRefPubMedGoogle Scholar
  5. 5.
    Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, et al (1996) Oral budesonide for active Crohn’s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 110:45–51PubMedGoogle Scholar
  6. 6.
    Thomsen OO, Cortot A, Jewell D, Wright JP, Winter T, Veloso FT, et al (1998) A comparison of budesonide and mesalamine for active Crohn’s disease. International Budesonide/Mesalamine Study Group. N Engl J Med 339:370–374CrossRefPubMedGoogle Scholar
  7. 7.
    Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al (1994) A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 331:842–845CrossRefPubMedGoogle Scholar
  8. 8.
    Hoffmann J, Zeitz M (2003) Chronically active Crohn’s disease. Z Gastroenterol 41:31–35CrossRefPubMedGoogle Scholar
  9. 9.
    Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, et al (1992) Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 102:1647–1653PubMedGoogle Scholar
  10. 10.
    Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H, et al (1984) European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment. Gastroenterology 86:249–266PubMedGoogle Scholar
  11. 11.
    Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al (1993) Azathioprine combined with prednisone or monotherapy with prednisolone in active Crohn’s disease. Gastroenterology 105:367–372PubMedGoogle Scholar
  12. 12.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104CrossRefPubMedGoogle Scholar
  13. 13.
    Camma C, Giunta M, Rosselli M, Cottone M, Sandborn W, Sutherland L, et al (1997) Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113:1465–1473PubMedGoogle Scholar
  14. 14.
    Cottone M, Camma C, Fellermann K, Steffen M, Stein J, Raedler A, et al (2000) Mesalamine and relapse prevention in Crohn’s disease. Gastroenterology 119:597PubMedGoogle Scholar
  15. 15.
    Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C, et al (2000) Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 2:CD000545PubMedGoogle Scholar
  16. 16.
    Pearson DC, May GR, Fick G, Sutherland LR, Ortiz Z, Shea B, et al (2000) Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst Rev 342:CD000067Google Scholar
  17. 17.
    Boulton-Jones JR, Pritchard K, Mahmoud AA, Hanauer SB, McDonald JW, Ortiz Z, et al (2000) The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 14:1561–1565CrossRefPubMedGoogle Scholar
  18. 18.
    Bouhnik Y, Lemann M, Mary JY, Scemama G, Tai R, Matuchansky C, et al (1996) Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 347:215–219CrossRefPubMedGoogle Scholar
  19. 19.
    Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, et al (2000) A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 342:1627–1632CrossRefPubMedGoogle Scholar
  20. 20.
    Ortiz Z, Shea B, Suarez Almazor M, Moher D, Wells G, Tugwell P (2000) Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2:CD000951PubMedGoogle Scholar
  21. 21.
    Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF (1999) Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 44:625–628PubMedGoogle Scholar
  22. 22.
    Fellermann K, Steffen M, Stein J, Raedler A, Hamling J, Ludwig D, et al (2000) Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 14:171–176CrossRefPubMedGoogle Scholar
  23. 23.
    Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT (2000) Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn’s disease. Inflamm Bowel Dis 6:16–20PubMedGoogle Scholar
  24. 24.
    Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, et al (2001) Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001–2003. Int J Colorectal Dis 16:1–11CrossRefPubMedGoogle Scholar
  25. 25.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al (2002) Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359:1541–1549CrossRefPubMedGoogle Scholar
  26. 26.
    Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR (2003) Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125:320–327CrossRefPubMedGoogle Scholar
  27. 27.
    Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, et al (2001) A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology 121:1064–1072PubMedGoogle Scholar
  28. 28.
    Schneider MU, Laudage G, Guggenmoos-Holzmann I, Riemann JF, Sutherland LR (1985) Metronidazole in the treatment of Crohn disease. Results of a controlled randomized prospective study. Dtsch Med Wochenschr 110:1724–1730PubMedGoogle Scholar
  29. 29.
    Pearson DC, May GR, Fick GH, Sutherland LR (1995) Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123:132–142PubMedGoogle Scholar
  30. 30.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, et al (1999) Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 340:1398–1405CrossRefPubMedGoogle Scholar
  31. 31.
    Veloso FT, Carvalho J, Magro F (1996) Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 23:29–34CrossRefPubMedGoogle Scholar
  32. 32.
    Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G, et al (2000) Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case–control study. Am J Gastroenterol 95:1949–1954PubMedGoogle Scholar
  33. 33.
    Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G, et al (2002) Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 46:328–346CrossRefPubMedGoogle Scholar
  34. 34.
    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193CrossRefPubMedGoogle Scholar
  35. 35.
    Tromm A, May D, Almus E, Voigt E, Greving I, Schwegler U, et al (2001) Cutaneous manifestations in inflammatory bowel disease. Z Gastroenterol 39:137–144CrossRefPubMedGoogle Scholar
  36. 36.
    Parlak E, Kosar Y, Ulker A, Dagli U, Alkim C, Sahin B, et al (2001) Primary sclerosing cholangitis in patients with inflammatory bowel disease in Turkey. J Clin Gastroenterol 33:299–301CrossRefPubMedGoogle Scholar
  37. 37.
    Zachos M, Tondeur M, Griffiths AM (2001) Enteral nutritional therapy for inducing remission of Crohn’s disease. Cochrane Database Syst Rev 3:CD000542PubMedGoogle Scholar
  38. 38.
    Heuschkel RB (2000) Enteral nutrition in children with Crohn’s disease. J Pediatr Gastroenterol Nutr 31:575CrossRefPubMedGoogle Scholar
  39. 39.
    Goh J, O’Morain CA (2003) Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 17:307–320CrossRefPubMedGoogle Scholar
  40. 40.
    Clements D, Compston JE, Evans WD, Rhodes J (1993) Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 34:1543–1546PubMedGoogle Scholar
  41. 41.
    Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P (2000) Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD000952PubMedGoogle Scholar
  42. 42.
    Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al (2000) Biphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2:CD001347PubMedGoogle Scholar
  43. 43.
    von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G, et al (2000) Increase of bone mineral density with sodium fluoride in patients with Crohn’s disease. Eur J Gastroenterol Hepatol 12:19–24PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Medizinische Klinik ICharité Universitätsmedizin BerlinBerlinGermany

Personalised recommendations